Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.71 |
| ▸ | POLB | P06746 | 2/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | NPC1 | O15118 | 9/20 | 0.58 |
| ▸ | RAB9A | P51151 | 8/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.58 |
| ▸ | PKM | P14618 | 4/20 | 0.58 |
| ▸ | MAOB | P27338 | 1/20 | 0.58 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | SCD | O00767 | 1/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL707871 | 0.83 | CYP3A4 (0.71) | CYP3A4POLBTDP1LMNANPC1 | |
| SCHEMBL29776932 | 0.83 | CYP3A4 (1.00) | CYP3A4POLBTDP1LMNANPC1 | |
| SCHEMBL28800545 | 0.83 | CYP3A4 (0.71) | CYP3A4POLBTDP1LMNANPC1 | |
| SCHEMBL707208 | 0.83 | CYP3A4 (1.00) | CYP3A4POLBTDP1LMNANPC1 | |
| Hydrochloric Acid SCHEMBL7080808 | 0.81 | CYP3A4 (0.69) | CYP3A4POLBTDP1LMNANPC1 | |
| SCHEMBL14395372 | 0.81 | ABL1 (0.48) | CYP3A4POLBTDP1MAPTLMNA | |
| SCHEMBL11734676 | 0.80 | NPC1 (0.68) | CYP3A4LMNANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL23566380 | 0.79 | NPC1 (0.75) | CYP3A4POLBTDP1LMNANPC1 | |
| SCHEMBL19820720 | 0.79 | LMNA (0.65) | CYP3A4POLBTDP1LMNANPC1 | |
| SCHEMBL204726 | 0.77 | NPC1 (0.73) | CYP3A4POLBTDP1LMNANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0049656-B1 | PURIFICATION DEVICE FOR REMOVING HEAVY METALS FROM CONTAMINATED AQUEOUS EFFLUENTS | Commissariat à l'Energie Atomique (FR) | 1985-05-29 | — | — | EP | claimed |
| US-20170037016-A1 | GUANIDINE COMPOUNDS AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | ABBVIE DEUTSCHLAND (DE) | 2017-02-09 | — | — | US | disclosed |
| US-9475782-B2 | Guanidine compounds, and use thereof as binding partners for 5-HT5 receptors | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-10-25 | — | — | US | disclosed |
| US-20130324537-A1 | GUANIDINE COMPOUNDS, AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | ABBOTT LABORATORIES (US) | 2013-12-05 | — | — | US | disclosed |
| US-8481576-B2 | Guanidine compounds, and use thereof as binding partners for 5-HT5 receptors | ABBOTT GMBH & CO. KG (DE) | 2013-07-09 | — | — | US | disclosed |
| US-8431604-B2 | Guanidine compounds, and use thereof as binding partners for 5-HT5 receptors | ABBOTT GMBH & CO. KG (DE) | 2013-04-30 | — | — | US | disclosed |
| US-20110237589-A1 | GUANIDINE COMPOUNDS, AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2011-09-29 | — | — | US | disclosed |
| US-20070299074-A1 | Guanidine Compounds, and Use Thereof as Binding partners for 5-Ht5 Receptors | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2007-12-27 | — | — | US | disclosed |
| EP-1709040-A2 | FIVE-MEMBERED HETEROCYCLIC COMPOUNDS AS INHIBITORS OF SRC FAMILY PROTEIN KINASE | Sirenade Pharmaceuticals AG (DE) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005068458-A2 | FIVE-MEMBERED HETEROCYCLIC COMPOUNDS AS INHIBITORS OF SRC FAMILY PROTEIN KINASE | SIRENADE PHARMACEUTICALS AG (DE) | 2005-07-28 | — | — | WO | disclosed |
| EP-1555264-A1 | Five-membered heterocyclic compounds as inhibitors of SRC family protein kinase. | Sireen AG (DE) | 2005-07-20 | — | — | EP | disclosed |
| CN-1069882-A | The Compounds and methods for that suppresses HIV and correlated virus | MEDIVIR AB (CH) | 1993-03-17 | — | — | CN | disclosed |
| EP-0049656-B1 | PURIFICATION DEVICE FOR REMOVING HEAVY METALS FROM CONTAMINATED AQUEOUS EFFLUENTS | Commissariat à l'Energie Atomique (FR) | 1985-05-29 | — | — | EP | disclosed |
| EP-0049656-A1 | Purification device for removing heavy metals from contaminated aqueous effluents | Commissariat à l'Energie Atomique (FR) | 1982-04-14 | — | — | EP | disclosed |
| EP-0049656-A1 | Purification device for removing heavy metals from contaminated aqueous effluents | Commissariat à l'Energie Atomique (FR) | 1982-04-14 | — | — | EP | disclosed |
| EP-0001949-A1 | Lubricant compositions that contain phosphorus and nitrogen | OROGIL (FR) | 1979-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130324537-A1 | GUANIDINE COMPOUNDS, AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | HTR5A, GRM5, TAAR5 | CYP3A4 3559/4885POLB 4113/4885TDP1 247/4885 |
| US-20170037016-A1 | GUANIDINE COMPOUNDS AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | HTR5A, GRM5, GRK5 | CYP3A4 3961/4885POLB 3967/4885TDP1 243/4885 |
| US-20070299074-A1 | Guanidine Compounds, and Use Thereof as Binding partners for 5-Ht5 Receptors | HTR5A, GRM5, TAAR5 | CYP3A4 3559/4885POLB 4113/4885TDP1 247/4885 |
| US-20110237589-A1 | GUANIDINE COMPOUNDS, AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | HTR5A, GRM5, TAAR5 | CYP3A4 3559/4885POLB 4113/4885TDP1 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.